BRIEF-Compass Therapeutics Provides Corporate Update

Compass Therapeutics, Inc. +0.37%

Compass Therapeutics, Inc.

CMPX

5.45

+0.37%

Jan 6 (Reuters) - Compass Therapeutics Inc. CMPX.O:

  • COMPASS THERAPEUTICS PROVIDES CORPORATE UPDATE

  • COMPASS THERAPEUTICS INC. - PHASE 1 STUDY OF CTX-10726 EXPECTED TO START IN Q1 2026, INITIAL DATA EXPECTED H2 2026

  • COMPASS THERAPEUTICS INC. - PFS AND OS ANALYSES FOR TOVECIMIG IN BTC ON TRACK FOR Q1 2026

  • COMPASS THERAPEUTICS: INITIATION OF PHASE 2 TRIAL OF CTX-471 IN PATIENTS WITH TUMORS EXPRESSING NCAM (CD56) EXPECTED H1 2026

Source text: ID:nGNX92z6dT

Further company coverage: CMPX.O


((Reuters.Briefs@thomsonreuters.com;))

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.